Interesting sentence:
'Should the synergies between FAK and immuno-oncology drugs such as checkpoint inhibitors be demonstrated clinically, we believe FAK assets will be in significant demand by leading cancer immunology firms.'
Considerinhg they are fast tracking clinical this year for reasons that are best listened to on their recent webinar, it won't be long until we'll know of big pharma will come knocking. That is, laater this year.
Ann: Acquisition of Amplia Therapeutics - Questions and Answers, page-2
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
-0.011(10.0%) |
Mkt cap ! $27.20M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 9.9¢ | $12.21K | 121.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 97518 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 50700 | 2 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| ATX (ASX) Chart |